Replies to post #23498 on CytoSorbents Corporation (CTSO)

[vinovista]

"While CytoSorb demand is likely to remain strong in the second quarter, we think the demand would likely weaken, extending through the rest of 2020, as the pandemic subsides resulting in lower revenues during this time. However, if there is a second and third resurgence from this virus, we could witness demand shooting up again for CytoSorb."
When was this statement made? If I remember it was a few weeks ago when we started to bend down. We are in the last week bending UP. Glad to see they have expansion at least on the table.
That was a good call on the first expansion agreed.

[Canes16]

Techxen, the only number that hasn't made sense to me thus far is the number of CV patients treated by Cytosorb. It's extremely low in my opinion. The last number that we heard was 750 patients. Hospitals may be ordering at a rapid rate, but are they using the filters? I was hoping to see the number of patients treated by Cytosorb in the thousands. That would get me more excited. Maybe we will see a larger increase during the Q2 earnings call.

I will continue to be disappointed with the lack of information coming from the company. In late March/early April, there were updates almost weekly. This week's PR was the first that we heard from the company in 3 weeks. I see no advertising for Cytosorb...why?

Too many questions still that need to be answered. Let's hope for a big revenue number from not only CV but from the company's normal business.

[Greenaccountingbean]

Anyone have a chance to check out this database? Are we in it? If so, how did we fair?


After saving his own life with a repurposed drug, a professor reviews every drug being tried against Covid-19 https://www.cnn.com/2020/06/27/health/coronavirus-treatment-fajgenbaum-drug-review-scn-wellness/index.html